ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FARN Faron Pharmaceuticals Oy

117.50
-0.50 (-0.42%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.42% 117.50 115.00 120.00 117.50 117.50 117.50 4,573 08:00:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -28.73M -0.4177 -2.81 80.82M
Faron Pharmaceuticals Oy is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharmaceuticals Oy was 118p. Over the last year, Faron Pharmaceuticals Oy shares have traded in a share price range of 117.50p to 360.00p.

Faron Pharmaceuticals Oy currently has 68,786,699 shares in issue. The market capitalisation of Faron Pharmaceuticals Oy is £80.82 million. Faron Pharmaceuticals Oy has a price to earnings ratio (PE ratio) of -2.81.

Faron Pharmaceuticals Oy Share Discussion Threads

Showing 1526 to 1546 of 1625 messages
Chat Pages: 65  64  63  62  61  60  59  58  57  56  55  54  Older
DateSubjectAuthorDiscuss
15/7/2020
08:54
Signs of life!
raldo
22/6/2020
11:20
This is a good reading:https://link.springer.com/article/10.1007/s00134-020-06086-3
yep1234
22/6/2020
11:08
Not for severe Ards patients
cwebb07
22/6/2020
11:07
Toffeeman, in COVID-19 patient’s lungs are filled with liquid. It is hard to inhale anything to your bloodstream. Maybe something will go through and help the patient, but a lot of it will stay out. All IMO of course.
yep1234
22/6/2020
10:42
Or SNG001 which will be administered pre-ICU!
toffeeman
22/6/2020
09:45
Toffeeman...Interferon should be issued early and without steroids and Faron IV format is best.Steroids can help at certain stages of ARDS much later down the process.Traumakine will be the real winner
cwebb07
22/6/2020
09:43
Immunomodulation is complex, and timing of the treatments is critical. There are a limited number of direct studies on the timing of immunomodulatory treatments such as IFN-beta, but given our basic understanding of human biology and viral defence, we suggest that IFN-beta should be given early to COVID-19 patients. In mild cases such as in the recent clinical trial, even s.c. administered IFN-beta was effective [1], but in more severe cases, i.v. injections are needed to rapidly reach the endothelium. As ARDS rises together with a cytokine storm, corticosteroids may play a beneficial role during the later fibrotic phase or just by calming down the cytokine storm after IFNs have had their impact. This is supported by Villar et al. who showed that the use of dexamethasone was associated with better survival in ARDS [12]. A notable feature of this study is that the enrolled patients were not on steroids when entering the trial
cwebb07
22/6/2020
09:16
That article references that.It's about when Traumakine is issued and how severe the patient is.They both have a benefit in covid..the difference being Traumakine will have an ongoing benefit with patients with ARDS not linked to Covid
cwebb07
22/6/2020
08:23
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5Think this explains Traumakine and the link to steroids and if proven in current trial then we will have lift off
cwebb07
20/6/2020
17:09
Maybe this link works instead:https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa350/5860074
yep1234
20/6/2020
17:08
Good reading from Oxford University press for the infectious Diseases Society of America regarding Interferon beta 1a (as is Traumakine, just i.v version of it) in SARS-Cov-2:https://watermark.silverchair.com/jiaa350.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAqowggKmBgkqhkiG9w0BBwagggKXMIICkwIBADCCAowGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMsR56W29h6cavBe6sAgEQgIICXSB5UUIsGKSV3BSOG3Zlu4ayNxGcctqtInfwcUyWXWByV_r9_ck2JBLqdz-pJZ-3KtDFXVUMb6kls_kd2N83HuYGD8LKFY_A9ZDgI-4vGEhD7YXLmlEs8RYSSXO4vOqtpXXVXhcDAZ168kPlu42AgUJX1CGApTrAMhNGi_zDQu_tGyVoD_YOABmNYNzp9E0SmX2zOzTg5uccLDI6aiCatOJw6Dxn4TPH66SoHDCnKtHE4gqI8tJbsmxUUqITQnX03n6IbSrYyi1DPW2SzhO0U39tEpNxLzfDL3gR88AJZekjeTsInHc5aYJlLeqIOxUVLKlOIbtssho0DmA_LcAEi7REeoRWVg0NydADPRGDhD2h1Rk-3bV3dkr5UDfRYg6mfxsDCSRw1Ef1C5p-eCY5FEwOm2ltPxDj1683isJX41TuETaS3dxO8L9mswQWw_IZKDt-7H26ExjX4-1l7hN3lmb9UtueAkQJzKTCxPicJnda9-Ozeb0uXwJgRMOJgHlwYZC0sxmB80CSfaQQEcIlncLVI675E8YkZjfnmpOnCPLM0LBraJ-8DV0xMoA14OOGbSZ_olJtUhz4ArSY2QdKOiraKIGgolDKnuMOZowa0v2En4KfKPwBqXpsU_2tewJkS-hDaSNfSF8K0Sfe-HqDS0fwIlIrrhoi3Oh1ij9DatzFrRtJQktcZjEcYDBz1kiYAC8DvTXRbodJpGom1vYkmD_fbhPW8CfgnWINl3qRUix-8Ha3Zh_CRI4eAnCyvw0gyA7bthkB-seWcc8o5ZoqIiGNFyrJINk0sh298roI
yep1234
19/6/2020
18:40
Slight concern that steroids are now being recommended to treat Covid 19 and yet the Trakumine trial is for patients excluding from using steroids. it will be an interesting outcome.
zipstuck
15/6/2020
09:59
Think you'll find they don't just thrown money away at any company. Underpins the funding as we move forward
bwgs
15/6/2020
09:24
You have to wonder what prompted this.

Feedback from Traumakine users?
Opportunitism. Take the loan because it is available now?

A current example of the benefits of having a having a specialised manufacturing capability is OXB.

hashertu
15/6/2020
08:39
Have to believe one day we will open up at £10+
cwebb07
13/6/2020
08:10
Faron's scientific network at work for COVID-19: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03048-5
yep1234
19/5/2020
16:20
Now that would be interesting for us
bwgs
19/5/2020
11:48
According to Faron's RNS regarding grant from Business Finland as part of Cancer IO on 11.5.2020:- Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium membershttps://cancerio.org/our-partners/From Cancer IO webpage partners include among others: Abbvie, AstraZeneca, Novartis, GSK, Pfizer, Roche.Does this mean Clevegen is to be studied in combination with the drugs of those big pharma companies?
yep1234
11/5/2020
17:29
https://cancerio.org/our-partners/
yep1234
05/5/2020
12:57
Trust this was the replacement for the company that pulled out last year ?
bwgs
05/5/2020
09:49
I think that news had been discounted already
toffeeman
Chat Pages: 65  64  63  62  61  60  59  58  57  56  55  54  Older

Your Recent History

Delayed Upgrade Clock